Aerie announces $75 million public stock offering

Aerie Pharmaceuticals has begun a registered underwritten public offering of $75 million of shares of its common stock, according to a company press release.
From the date of the offering, the underwriter will have a 30-day option to purchase up to an additional $11.25 million of shares.
The company will use the proceeds of the offering to fund its commercialization programs for Rhopressa and Roclatan in North America, as well as clinical and commercialization efforts outside of North America, and to develop other potential pipeline opportunities, the release said.

Full Story →